Prelude Therapeutics (PRLD)
Prelude Therapeutics Statistics
Share Statistics
Prelude Therapeutics has 56.45M shares outstanding. The number of shares has increased by 0.41% in one year.
| Shares Outstanding | 56.45M |
| Shares Change (YoY) | 0.41% |
| Shares Change (QoQ) | 0.22% |
| Owned by Institutions (%) | 42.4% |
| Shares Floating | 35.17M |
| Failed to Deliver (FTD) Shares | 875 |
| FTD / Avg. Volume | 0.42% |
Short Selling Information
The latest short interest is 2.38M, so 4.32% of the outstanding shares have been sold short.
| Short Interest | 2.38M |
| Short % of Shares Out | 4.32% |
| Short % of Float | 13.63% |
| Short Ratio (days to cover) | 7.5 |
Valuation Ratios
The PE ratio is -0.76 and the forward PE ratio is -0.89. Prelude Therapeutics's PEG ratio is 0.04.
| PE Ratio | -0.76 |
| Forward PE | -0.89 |
| PS Ratio | 13.75 |
| Forward PS | 0.5 |
| PB Ratio | 0.73 |
| P/FCF Ratio | -0.93 |
| PEG Ratio | 0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Prelude Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.3, with a Debt / Equity ratio of 0.14.
| Current Ratio | 5.3 |
| Quick Ratio | 5.3 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | -0.13 |
| Debt / FCF | -0.17 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $53.44K |
| Profits Per Employee | $-970.79K |
| Employee Count | 131 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -77% in the last 52 weeks. The beta is 1.34, so Prelude Therapeutics's price volatility has been higher than the market average.
| Beta | 1.34 |
| 52-Week Price Change | -77% |
| 50-Day Moving Average | 0.76 |
| 200-Day Moving Average | 2.17 |
| Relative Strength Index (RSI) | 60.37 |
| Average Volume (20 Days) | 210.23K |
Income Statement
In the last 12 months, Prelude Therapeutics had revenue of 7M and earned -127.17M in profits. Earnings per share was -1.68.
| Revenue | 7M |
| Gross Profit | 7M |
| Operating Income | -139.71M |
| Net Income | -127.17M |
| EBITDA | -139.71M |
| EBIT | -139.71M |
| Earnings Per Share (EPS) | -1.68 |
Balance Sheet
The company has 12.47M in cash and 18.02M in debt, giving a net cash position of -5.55M.
| Cash & Cash Equivalents | 12.47M |
| Total Debt | 18.02M |
| Net Cash | -5.55M |
| Retained Earnings | -583.56M |
| Total Assets | 175.51M |
| Working Capital | 110.25M |
Cash Flow
In the last 12 months, operating cash flow was -102.89M and capital expenditures -764K, giving a free cash flow of -103.65M.
| Operating Cash Flow | -102.89M |
| Capital Expenditures | -764K |
| Free Cash Flow | -103.65M |
| FCF Per Share | -1.37 |
Margins
Gross margin is 100%, with operating and profit margins of -1995.91% and -1816.76%.
| Gross Margin | 100% |
| Operating Margin | -1995.91% |
| Pretax Margin | -1816.76% |
| Profit Margin | -1816.76% |
| EBITDA Margin | -1995.91% |
| EBIT Margin | -1995.91% |
| FCF Margin | -1480.74% |
Dividends & Yields
PRLD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for PRLD is $4, which is 349.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 349.4% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -5.77 |
| Piotroski F-Score | 3 |